Mouse Tumor Models for Advanced Cancer Immunotherapy

Chulpanova, Daria S.; Kitaeva, Kristina V.; Rutland, Catrin S.; Rizvanov, Albert A.; Solovyeva, Valeriya V.

doi:10.3390/ijms21114118

Cited by 93 publications

(73 citation statements)

References 115 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, following long-term cultivation of tumor cell lines, the genetic heterogeneity of the original tumor is excluded [ 11 ]. Research can also be carried out on tumor xenografts, but it is expensive and quite a time-consuming procedure [ 12 ]. The solution to this problem is 3D tumor model development, which would accurately mimic the features of the tumor and tumor microenvironment (TME).…”

Section: Introductionmentioning

confidence: 99%

Promising Applications of Tumor Spheroids and Organoids for Personalized Medicine

Gilazieva

Ponomarev

Rutland

et al. 2020

Cancers

Self Cite

101

View full text Add to dashboard Cite

One of the promising directions in personalized medicine is the use of three-dimensional (3D) tumor models such as spheroids and organoids. Spheroids and organoids are three-dimensional cultures of tumor cells that can be obtained from patient tissue and, using high-throughput personalized medicine methods, provide a suitable therapy for that patient. These 3D models can be obtained from most types of tumors, which provides opportunities for the creation of biobanks with appropriate patient materials that can be used to screen drugs and facilitate the development of therapeutic agents. It should be noted that the use of spheroids and organoids would expand the understanding of tumor biology and its microenvironment, help develop new in vitro platforms for drug testing and create new therapeutic strategies. In this review, we discuss 3D tumor spheroid and organoid models, their advantages and disadvantages, and evaluate their promising use in personalized medicine.

show abstract

Section: Introductionmentioning

confidence: 99%

Promising Applications of Tumor Spheroids and Organoids for Personalized Medicine

Gilazieva

Ponomarev

Rutland

et al. 2020

Cancers

Self Cite

101

View full text Add to dashboard Cite

show abstract

“…Gliomas grown through syngeneic induction present as well-circumscribed tumors without infiltration into the surrounding brain parenchyma, which is not the typical growth pattern appreciated in human astrocytoma [22]. Therefore, these models do not fully recapitulate the phenotypic characteristics of the tumor being studied [14,130].…”

Section: Syngeneic Modelsmentioning

confidence: 96%

“…Around the time that the first xenograft models were established, syngeneic models were created to facilitate the identification of effective chemotherapies [14,15]. From the 1950s to 1970s, the National Cancer Institute conducted chemotherapeutic screening programs using syngeneic models of sarcoma 180, L1210 leukemia, B16 melanoma, and P388 leukemia, among others [12].…”

Section: Evolution Of Cancer Mouse Modelsmentioning

confidence: 99%

Contemporary Mouse Models in Glioma Research

Hicks¹,

Bird²,

Abdullah³

2021

Preprint

View full text Add to dashboard Cite

Despite advances in understanding of the molecular pathogenesis of glioma, outcomes remain dismal. Developing successful treatments for glioma requires faithful in vivo disease modeling and rigorous preclinical testing. Murine models, including xenograft, syngeneic, and genetically engineered models, are used to study gliomagenesis, identify methods of tumor progression, and test novel treatment strategies. Since the discovery of highly recurrent isocitrate dehydrogenase (IDH) mutations in lower-grade gliomas, there is increasing emphasis on effective modeling of IDH mutant brain tumors. Improvements in preclinical models that capture the phenotypic and molecular heterogeneity of gliomas are critical for the development of effective new therapies. Herein, we explore the current status, advancements, and challenges with contemporary murine glioma models.

show abstract

“…Overall, CAR-transduced macrophages significantly improved the survival rates of immunodeficient NOD/SCID mice. Moreover, they have a potential for even stronger impact on the survival of immunocompetent mice with functional T-cells due to the epitope spreading effect [ 32 ].…”

Section: Car Cells But Not Car αβ T-cellsmentioning

confidence: 99%

Adoptive Immunotherapy beyond CAR T-Cells

Titov

Zmievskaya

Ganeeva

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

Adoptive cell immunotherapy (ACT) is a vibrant field of cancer treatment that began progressive development in the 1980s. One of the most prominent and promising examples is chimeric antigen receptor (CAR) T-cell immunotherapy for the treatment of B-cell hematologic malignancies. Despite success in the treatment of B-cell lymphomas and leukemia, CAR T-cell therapy remains mostly ineffective for solid tumors. This is due to several reasons, such as the heterogeneity of the cellular composition in solid tumors, the need for directed migration and penetration of CAR T-cells against the pressure gradient in the tumor stroma, and the immunosuppressive microenvironment. To substantially improve the clinical efficacy of ACT against solid tumors, researchers might need to look closer into recent developments in the other branches of adoptive immunotherapy, both traditional and innovative. In this review, we describe the variety of adoptive cell therapies beyond CAR T-cell technology, i.e., exploitation of alternative cell sources with a high therapeutic potential against solid tumors (e.g., CAR M-cells) or aiming to be universal allogeneic (e.g., CAR NK-cells, γδ T-cells), tumor-infiltrating lymphocytes (TILs), and transgenic T-cell receptor (TCR) T-cell immunotherapies. In addition, we discuss the strategies for selection and validation of neoantigens to achieve efficiency and safety. We provide an overview of non-conventional TCRs and CARs, and address the problem of mispairing between the cognate and transgenic TCRs. Finally, we summarize existing and emerging approaches for manufacturing of the therapeutic cell products in traditional, semi-automated and fully automated Point-of-Care (PoC) systems.

show abstract

Mouse Tumor Models for Advanced Cancer Immunotherapy

Cited by 93 publications

References 115 publications

Promising Applications of Tumor Spheroids and Organoids for Personalized Medicine

Promising Applications of Tumor Spheroids and Organoids for Personalized Medicine

Contemporary Mouse Models in Glioma Research

Adoptive Immunotherapy beyond CAR T-Cells

Contact Info

Product

Resources

About